Spain’s Sanifit heads to Phase III with €72.2M in new funding

With €72.2 million ($82.1 million) in fresh cash to fund a Phase III study of its lead candidate to treat a rare vascular calcification disorder, Sanifit is looking ahead to additional Phase IIb trial results

Read the full 352 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE